Role of chemiluminescence interferon gamma release assay in auxiliary diagnosis of pulmonary tuberculosis

doi:10.3969/j.issn.1673-8640.2023.03.010

Abstract

Abstract: Objective To investigate the clinical application value of chemiluminescence interferon gamma release assay in the auxiliary diagnosis of pulmonary tuberculosis. Methods Totally，183 pulmonary tuberculosis patients and 33 healthy subjects in Weifang People's Hospital from March 1，2019 to December 31，2020 were enrolled. They were classified into active pulmonary tuberculosis group（109 cases）and inactive pulmonary tuberculosis group（74 cases）. The performance of chemiluminescence interferon gamma release assay，tuberculin skin allergy test，T-SPOT TB test and blood routine test were evaluated. The difference of blood routine test positive and negative results in chemiluminescence interferon gamma release assay for active pulmonary tuberculosis group was compared. Results The positive rates of active pulmonary tuberculosis group，inactive pulmonary tuberculosis group and healthy control group were 92.66%，62.16% and 9.09% by chemiluminescence interferon gamma release assay，respectively（P<0.05）. The sensitivities of chemiluminescence interferon gamma release assay，tuberculin skin allergy test and T-SPOT TB test had statistical significance（P<0.05），and the specificities，positive predictive values and negative predictive values had no statistical significance（P>0.05）. The sensitivity，specificity，positive predictive value and negative predictive value of chemiluminescence interferon gamma release assay were slightly higher than those of T-SPOT TB test（P>0.05）. There was no statistical significance in the absolute value of white blood cell，the absolute value of lymphocyte and the percentage of lymphocyte in peripheral blood between chemiluminescence interferon gamma release assay positive and negative patients in active pulmonary tuberculosis group（P>0.05）. Conclusions Chemiluminescence interferon gamma release assay is convenient and rapid and has certain guiding significance for the auxiliary diagnosis of pulmonary tuberculosis.

Key words: Interferon gamma release assay, Chemiluminescence, Pulmonary tuberculosis

CLC Number:

R446.61

GAI Linlin, LI Haibo, CHU Jinjin, SUN Jiamei, YAN Xinyi, DU Jinke, DAI Wenqing, XU Donghua. Role of chemiluminescence interferon gamma release assay in auxiliary diagnosis of pulmonary tuberculosis[J]. Laboratory Medicine, 2023, 38(3): 257-260.

Figures/Tables 3

References 18

[1]	HARDING E. WHO global progress report on tuberculosis elimination[J]. Lancet Respir Med, 2020, 8(1):19. DOI PMID
[2]	CHAKAYA J, KHAN M, NTOUMI F, et al. Global tuberculosis report 2020-reflections on the global TB burden,treatment and prevention efforts[J]. Int J Infect Dis, 2021, 113(Suppl 1):S7-S12. DOI URL
[3]	KANG W L, WANG G R, WU M Y, et al. Interferon-gamma release assay is not appropriate for the diagnosis of active tuberculosis in high-burden tuberculosis settings:a retrospective multicenter investigation[J]. Chin Med J(Engl), 2018, 131(3):268-275.
[4]	SIA J K, RENGARAJAN J. Immunology of Mycobacterium tuberculosis infections[J]. MicrobiolSpectr, 2019, 7(4):10.
[5]	结核病分类(WS196—2017)[J]. 新发传染病电子杂志, 2018, 3(3):191-192.
[6]	COMELLA-DEL-BARRIO P, DE SOUZA-GALVÃO M L, PRAT-AYMERICH C, et al. Impact of COVID-19 on tuberculosis control[J]. Arch Bronconeumol, 2021, 57:5-6.
[7]	World Health Organization. Global tuberculosis report 2020[EB/OL]. (2020-10-15)[2020-10-30]. .
[8]	LIU Y H, CHEN S, GAO J T, et al. The China tuberculosis clinical trials consortium network:a model for international TB clinical trials capacity building[J]. Infect Dis Poverty, 2020, 9(1):52. DOI
[9]	RUAN Q, ZHANG S, AI J, et al. Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients:a systemic review and meta-analysis[J]. Clin Rheumatol, 2016, 35(2):417-425. DOI URL
[10]	BEGLINGER C, DUDLER J, MOTTET C, et al. Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy[J]. Swiss Med Wkly, 2007, 137(43-44):620-622. DOI PMID
[11]	PERSON A K, PETTIT A C, STERLING T R. Diagnosis and treatment of latent tuberculosis infection:an update[J]. Curr Respir Care Rep, 2013, 2(4):199-207. DOI URL
[12]	SANTOS J A, DUARTE R, NUNES C. Host factors associated to false negative and indeterminate results in an interferon-γ release assay in patients with active tuberculosis[J]. Pulmonology, 2020, 26(6):353-362. DOI PMID
[13]	王新宁, 施旭东. 化学发光法结核分枝杆菌特异性细胞免疫反应检测在肺结核辅助诊断中的价值[C]. 中华医学会结核病学分会2019年全国结核病学术大会论文汇编, 2019:439.
[14]	AI L, FENG P, CHEN D, et al. Clinical value of interferon-γ release assay in the diagnosis of active tuberculosis[J]. Exp Ther Med, 2019, 18(2):1253-1257. DOI PMID
[15]	孙丹雄. γ-干扰素释放试验假阴性影响因素研究进展[J]. 国际呼吸杂志, 2020, 40(22):1756-1760.
[16]	陈诚, 杨健, 高海燕, 等. γ-干扰素释放试验结果的评价与定量界值的探索[J]. 国际呼吸杂志, 2018, 38(17):1299-1305.
[17]	马进宝, 马婷婷, 任斐, 等. 涂阳肺结核患者γ-干扰素释放试验假阴性的影响因素分析[J]. 中国防痨杂志, 2020, 42(12):1299-1304.
[18]	LV D, LIU Y, GUO F, et al. Combining interferon-γ release assays with lymphocyte enumeration for diagnosis of Mycobacterium tuberculosis infection[J]. J Int Med Res, 2020, 48(6):300060520925660.

组别	例数	年龄/岁	性别
组别	例数	年龄/岁	女/例	男/例
对照组	33	43.58±12.52	15	18
活动性肺结核组	109	50.45±12.91	26	83
非活动性肺结核组	74	51.61±13.59	23	51
统计值		3.378	5.783
P值		0.36	0.056

组别	例数	年龄/岁	性别
组别	例数	年龄/岁	女/例	男/例
对照组	33	43.58±12.52	15	18
活动性肺结核组	109	50.45±12.91	26	83
非活动性肺结核组	74	51.61±13.59	23	51
统计值		3.378	5.783
P值		0.36	0.056

组别	例数	阳性/ [例（%）]	阴性/ [例（%）]
活动性肺结核组	109	101（92.66）	8（7.34）
非活动性肺结核组	74	46（62.16）	28（37.84）
对照组	33	3（9.09）	30（90.91）
统计值		100.94
P值		<0.05

组别	例数	阳性/ [例（%）]	阴性/ [例（%）]
活动性肺结核组	109	101（92.66）	8（7.34）
非活动性肺结核组	74	46（62.16）	28（37.84）
对照组	33	3（9.09）	30（90.91）
统计值		100.94
P值		<0.05

方法	敏感性	特异性	阳性预测值	阴性预测值
化学发光法干扰素-γ释放试验	92.66（101/109）^*	90.91（30/33）	97.12（101/104）	78.95（30/38）
结核菌素皮内试验	71.56（78/109）	90.32（28/33）	93.96（78/83）	47.46（28/59）
T-SPOT TB试验	88.07（96/109）^*	84.84（28/33）	95.05（96/101）	68.29（28/41）